Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Walvax PPV23 vs Pneumovax 23 in Chinese Adults and Children
NCT02285036Phase 3Completed
- Sponsor
- Walvax Biotechnology Co., Ltd.
- Start
- Sep 2012
- Primary completion
- Dec 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Walvax PPSV23 in pneumococcal disease (2 arms), sponsored by Walvax Biotechnology Co., Ltd. Primary endpoint: Rate of 2-fold increase of anti-pneumococcal antibody at 30 days. Started Sep 2012; status: completed.
02
Drugs
Walvax PPSV23
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT02285036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285036.